Renaissance Capital logo

ZNTL News

Renaissance Capital's 2Q 2020 US IPO Market Review

Zentalis Pharmaceuticals logo

The IPO Market Stages a Swift Recovery The second quarter saw 38 IPOs raise $15 billion. After coronavirus volatility caused the slowest April and May since the Great Recession, IPO activity roared back in June, buoyed by stellar returns. During the...read more

2020 biotech IPOs now average an 80% return from their offer price

Zentalis Pharmaceuticals logo

The 2020 US biotech IPO class closed Wednesday with an 80% average return from the offering price, a historic run-up for the year's 23 development-stage drug developers. The group has averaged a 36% pop on day one, and then 35% from there. Biotechs make up 70%...read more

The IPO market’s slowest spring since the financial crisis

Zentalis Pharmaceuticals logo

Sign Up For a Free Trial of ...read more

US IPO Week Ahead: An empty calendar and a quiet week for the IPO market

ACI

There are no IPOs scheduled for the week ahead. The most likely April IPOs Despite the encouraging market rally this past week, the Renaissance IPO Volatility Index is still about double the five-year average and few companies have filed, indicating the IPO ...read more